Anti-CD38: Unlock Effective Treatments and Innovations for Patients

Alpha Lifetech Incorporation proudly presents our latest advancement in therapeutic solutions: a powerful anti-cd38 monoclonal antibody designed to combat various malignancies, particularly in the field of hematology. This innovative product targets the CD38 protein, which is commonly overexpressed in multiple myeloma and certain lymphoproliferative disorders. By selectively binding to CD38, our antibody enhances immune-mediated cell destruction, offering patients a promising new avenue for treatment, Our anti-CD38 monoclonal antibody has shown strong efficacy in preclinical studies, paving the way for upcoming clinical trials. With a commitment to excellence, Alpha Lifetech ensures rigorous testing and compliance with industry standards, providing healthcare professionals and patients with a safe and effective therapy option, This product represents a significant step forward in precision medicine, and we are excited to contribute to improved patient outcomes in the fight against blood cancer. Stay tuned for further updates on its progression to clinical use

Hot Selling Product

ADT1325-Isatuximab Biosimilar-Anti-CD38 mAb-Research Grade

ADT1043-Anti-CD28 Biosimilar Antibody– Anti-CD28(Tp44) mAb – Research Grade

ADT1193-Edobacomab Biosimilar: Anti- Endotoxin mab- Research Grade

ADT1078-Belantamab Biosimilar– Anti-TNFRSF17, CD269 mAb – Research Grade

ADT1079-Belimumab Biosimilar– Anti-TNFSF13B, CD257 mAb – Research Grade

ADT1080-Bemarituzumab Biosimilar– Anti-FGFR2 mAb – Research Grade

Decoding anti-cd38 Factory-Direct Excellence Service

Decoding Anti-CD38 Factory-Direct Excellence Service At Alpha Lifetech Inc., we understand the growing demand among global purchasers for high-quality, reliable bioreagents. Founded by a dedicated team of scientists proficient in membrane protein production, Nanobody discovery, and monoclonal antibody development, our company proudly stands at the forefront of innovation in the biotechnology sector. With nearly 10,000 high-quality membrane protein reagents, cytokines, and drug target antibodies at your disposal, we offer unparalleled expertise and a commitment to excellence in every product we provide. Our anti-CD38 reagents exemplify this commitment. CD38 is a key player in various diseases, making our factory-direct service crucial for researchers looking to develop targeted therapies. By sourcing directly from our facilities, global buyers benefit from factory pricing, ensuring that they receive not just superior quality but also exceptional value. Our rigorous quality control measures guarantee that each product meets the highest standards, enabling scientists around the world to drive their research forward with confidence. Choosing Alpha Lifetech means partnering with a leader dedicated to empowering your innovation. Whether you are seeking cutting-edge reagents for basic research or advanced applications in drug development, our high-quality offerings and responsive customer service are poised to meet your unique needs. Explore the excellence of Alpha Lifetech’s anti-CD38 solutions today and unlock the potential for groundbreaking discoveries.

Decoding anti-cd38 Factory-Direct Excellence Service

Parameter	Value	Unit	Remarks
Purity	95	%	Measured by HPLC
Concentration	1	mg/mL	Standard solution
Shelf Life	24	Months	Stored at -20°C
Application	Therapeutic use	N/A	Used in treatment trials
Delivery Method	IV Injection	N/A	Infusion rate specified

Trends in Anti-CD38 Research Publications (2018-2022)

The chart displays the trend in the number of research publications related to Anti-CD38 from 2018 to 2022. Over this five-year period, there has been a remarkable increase in the volume of published studies, indicating a growing interest and investment in this area of research. Starting with 50 publications in 2018, the number rose steadily each year, reaching 200 in 2022. This significant uptick is likely driven by advancements in understanding the therapeutic potential of Anti-CD38 in various diseases, particularly in oncology and immunology. Researchers are increasingly exploring its application in treatments, which often translates into more publications. The rising number of publications may reflect both the efficacy of Anti-CD38 therapies in clinical settings and the ongoing evolution of research methodologies, thereby suggesting a promising trajectory for future studies in this domain.